Hochman David P 4
4 · Orchestra BioMed Holdings, Inc. · Filed Jun 2, 2026
Research Summary
AI-generated summary of this filing
Orchestra BioMed (OBIO) CEO David P. Hochman Buys 5,000 Shares
What Happened
- David P. Hochman, Chief Executive Officer and Chairperson of Orchestra BioMed (OBIO), acquired 5,000 shares in an open-market purchase on 2026-06-01. The reported weighted-average price was $3.83, for an aggregate value of about $19,150.
Key Details
- Transaction type: Purchase (code P) — open market/private purchase.
- Transaction date: 2026-06-01; Form 4 filed 2026-06-02 (timely filing).
- Price reported: $3.83 weighted average; actual trade prices ranged from $3.80 to $3.91 (footnote F1).
- Shares owned after transaction: Not specified in the provided filing details.
- Footnote: The filing notes multiple trades within the $3.80–$3.91 range and offers to provide per-price breakdown on request.
Context
- Purchases by company insiders (especially CEOs) are often viewed as a stronger signal than routine sales because they require personal capital outlay, though filings do not reveal motivation. This was a direct purchase, not an option exercise, gift, or tax withholding.
Insider Transaction Report
Form 4
Hochman David P
DirectorSee Remarks
Transactions
- Purchase
Common Stock, par value $0.0001 per share ("Common Stock")
[F1]2026-06-01$3.83/sh+5,000$19,150→ 1,064,029 total
Holdings
- 439,482(indirect: By Trust)
Common Stock
- 2,000(indirect: By Trust)
Common Stock
- 2,000(indirect: By Trust)
Common Stock
- 2,000(indirect: By Trust)
Common Stock
- 3,140(indirect: By Trust)
Common Stock
Footnotes (1)
- [F1]The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.80 to $3.91. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Signature
/s/ Andrew Taylor, Attorney-in-Fact|2026-06-02